Sanofi Q1 profit slips on generic competition, forex effects

Reuters04-25

By Ludwig Burger (Reuters) -Sanofi reported on Thursday that its first-quarter operating income declined 14.7%, as unfavourable currency effects and cheap competition to multiple sclerosis drug ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2430942868?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LDNg6R63_tclCQQmyNXh9w--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters-finance.com/088ab0c1350a4ee47be3d6c8e21bc12e","is_english":true,"pubTime":"2024-04-25 13:32","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2430942868","market":"us","top_or_hot":-1,"title":"Sanofi Q1 profit slips on generic competition, forex effects","media":"Reuters","content":"<div>\n<p>By Ludwig Burger \n (Reuters) -Sanofi reported on Thursday that its first-quarter operating income declined 14.7%, as unfavourable currency effects and cheap competition to multiple sclerosis drug ...</p>\n\n<a href=\"https://finance.yahoo.com/news/sanofi-q1-profit-slips-generic-053237018.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Q1 profit slips on generic competition, forex effects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Q1 profit slips on generic competition, forex effects\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-25 13:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/sanofi-q1-profit-slips-generic-053237018.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Ludwig Burger \n (Reuters) -Sanofi reported on Thursday that its first-quarter operating income declined 14.7%, as unfavourable currency effects and cheap competition to multiple sclerosis drug ...</p>\n\n<a href=\"https://finance.yahoo.com/news/sanofi-q1-profit-slips-generic-053237018.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://finance.yahoo.com/news/sanofi-q1-profit-slips-generic-053237018.html","article_id":"2430942868","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LDNg6R63_tclCQQmyNXh9w--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters-finance.com/088ab0c1350a4ee47be3d6c8e21bc12e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2430942868","pubTimestamp":1714023157,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":" -Sanofi reported on Thursday that its first-quarter operating income declined 14.7%, as unfavourable currency effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent.The French drugmaker said in a statement that operating income, adjusted for one-offs, slipped to 2.84 billion euros , a touch above the 2.79 billion euros expected on average by analysts in a poll on the company's website.The company reiterated it expects 2024 adjusted earnings per share  to slip by a \"low single-digit\" percentage, excluding currency swings, citing higher taxes and an increase in development expenditure.Currency changes would drag 2024 earnings lower by between 5.5% and 6.5% at current rates, it added. Finance chief Francois-Xavier Roger said in a media call that the decline in the Argentine Peso was a particular drag on first-quarter overseas sales.CFO Roger, previously at Nestle, said that preparations to list the Consumer Healthcare d","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","SNY":"赛诺菲安万特","SNYNF":"Sanofi","BK4585":"ETF&股票定投概念","BK4588":"碎股"},"translate_title":"赛诺菲Q1的利润下滑是由于仿制药竞争和外汇效应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNYNF":1,"SNY":0.9},"content_text":"By Ludwig Burger \n (Reuters) -Sanofi reported on Thursday that its first-quarter operating income declined 14.7%, as unfavourable currency effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent. \n The French drugmaker said in a statement that operating income, adjusted for one-offs, slipped to 2.84 billion euros ($3.04 billion), a touch above the 2.79 billion euros expected on average by analysts in a poll on the company's website. \n The company reiterated it expects 2024 adjusted earnings per share (EPS) to slip by a \"low single-digit\" percentage, excluding currency swings, citing higher taxes and an increase in development expenditure. \n Currency changes would drag 2024 earnings lower by between 5.5% and 6.5% at current rates, it added. Finance chief Francois-Xavier Roger said in a media call that the decline in the Argentine Peso was a particular drag on first-quarter overseas sales. \n Quarterly sales of eczema and asthma drug Dupixent jumped a currency-adjusted 25% to 2.84 billion euros, in line with analyst expectations and accounting for 27% of group sales. \n CFO Roger, previously at Nestle, said that preparations to list the Consumer Healthcare division on the Paris stock exchange from the fourth quarter were fully on track but other options, such as a sale, were not off the table. \n ($1 = 0.9338 euros) \n (Reporting by Ludwig Burger; Editing by Benoit Van Overstraeten and Subhranshu Sahu)","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2430942868"}